Belgian biotech ThromboGenics has announced it will change its name to Oxurion in the next few weeks. The stock ticker symbol will change to OXUR.
Chief executive Patrik De Haes said: “The new name, Oxurion, is designed to better reflect our ambition to deliver best in class therapies for back of the eye disorders,” and “we are also expanding our drug development efforts into new back of the eye indications where there is clear need for improved therapeutic options.”
Source: The Pharma Letter
Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.
Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.
The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).